Stephanie Baum | WRAL TechWire
Stephanie Baum

Stephanie Baum


Posts by Stephanie Baum


JOBS bill boon or bust for early-stage funding, IPOs, investors?

The U.S. Senate has approved a bill that will make it easier for early stage companies to raise money by broadening the number of people that can invest in them and help companies file for initial public offerings. But will it mean more biotechnology startups will have the money to survive the multiyear journey to bring their therapeutics or drugs to the finish line of regulatory approval and commercialization? Or will it lead to more companies competing for smaller amounts of money? James Greenwood, the president and CEO of the Biotechnology Industry Organization, said the Jumpstart Our Business Startups...

Read More

East Coast accelerator DreamIt adds minority-led startup programs

PHILADELPHIA, Pa. – East Coast technology accelerator DreamIt Ventures has launched its second new program in as many months – the latest focusing on minority-led startups. DreamIt Access will consist of five minority-led businesses in each DreamIt Ventures class from now on, starting with the summer class in New York City, said William Crowder of DreamIt Ventures. Applications for New York opened late last year and the early decision deadline is Feb. 22, followed by a final deadline of May 16. The move formalizes a program developed last year. Last fall, the Philadelphia-based accelerator had a minority entrepreneur accelerator...

Read More

GSK ends $150M licensing deal with NJ-based drug firm

Unigene Laboratories is looking for a new partner to commercialize its oral formulation of recombinantly produced parathyroid hormone osteoporosis drug for postmenopausal women after GlaxsoSmithKline (NYSE:GSK) decided to end a nine-year-old licensing deal with the Boonton, New Jersey drug developer. Unigene hosted a conference call following the announcement in which CEO Ashleigh Palmer was forced to parry some tough questions from analysts uncommonly frank in questioning the company’s future over the deal’s derailment. Under the terms of the original agreement, GSK was to receive an exclusive worldwide license to develop and commercialize the product. In return, it agreed to...

Read More